ClinicalTrials.gg
RecruitingNCT07755436Updated Sep 3, 2026

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

A Phase 1 interventional study of ARR-002 in Ovarian Cancer, Endometrial Cancer and Platinum-resistant Ovarian Cancer (PROC), sponsored by ArriVent BioPharma, Inc.. Recruiting at 6 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by ArriVent BioPharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
272nd of 1,498
180 · median 47
Started
2026
with 64 others
Phase 1
547 of 1,779
73 open now
Primary completion
2027-08
later than 234 of 452 live
Registered
1,761st of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 272nd largest by planned enrollment of the 1,498 interventional ones that give a count, is one of 65 that started in 2026, is one of 547 in phase 1, reaches primary completion later than 234 of the 452 other live ones, and was the 1,761st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

272 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

Read the detailed description

This is an open-label, multicenter Phase 1a/1b dose-escalation/expansion, consecutive-cohort, to assess safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of ARR-002 in adults with locally advanced or metastatic ovarian or endometrial cancer.

The study will consist of 2 main parts:

  • Phase 1a will enroll participants with platinum-resistant ovarian cancer (PROC). This dose-escalation portion will assess the safety and tolerability of ARR-002.
  • Phase 1b will enroll cohorts of participants by cancer type; platinum-resistant ovarian cancer (PROC) and endometrial cancer.
03

Conditions studied

  • Ovarian Cancer
  • Endometrial Cancer
  • Platinum-resistant Ovarian Cancer (PROC)
  • Metastatic Ovarian Cancer
  • Metastatic Endometrial Cancer

Keywords

  • PROC
  • ARR-002
  • ARR002
  • Advanced Ovarian Cancer
  • Metastatic Ovarian Cancer
  • Endometrial Cancer
  • Platinum-resistant Ovarian Cancer
  • antibody drug conjugates
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with and cytologically confirmed advanced or ovarian, primary peritoneal, or fallopian tube cancer, and platinum resistant who have failed or intolerant to standard therapy, or without alternative standard therapy.
  • Patients must have at least one according to the (RECIST v1.1).
  • Tumor specimen available for testing, or agree to at baseline.
  • The score of (ECOG) performance status of 0 or 1.
  • ≥ 12 weeks.
  • Organ functions and coagulation function must meet the basic requirements.
  • Patients with must use effective during the treatment and for 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with auristatin-derived drugs s (eg, MMAE and monomethyl auristatin F [MMAF]).
  • Received antitumor therapy within 4 weeks prior to the first dose or 5 half-lives, whichever is shorter.
  • Infection of active , active , or .
  • Symptomatic Central nervous system and/or meninges .
  • History of uncontrolled diabetes mellitus or diabetic neuropathy within 3 months before the first dose of study treatment.
  • Previous drug-induced interstitial lung disease (ILD) or active ILD.
  • Poorly controlled pleural, peritoneal, and pelvic effusion, or combined pericardial effusion.
  • History of recurrent gastrointestinal (GI) obstruction.
  • Patients with more than one cancer.
  • Any other diseases, pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding
  • Grade ≥ 2 peripheral neuropathy
  • History of severe cardiovascular diseases.
  • Current use of anticoagulants or thrombolytic agents for therapeutic purposes.
  • Known allergic reactions to any component of ARR-002.
  • Prior treatment with MUC16- or NaPi2b-targeting agents.
  • Ocular conditions such as keratitis or corneal ulceration, monocularity, corneal transplantation, uncontrolled retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disorder.
  • Other situations that are not suitable to participate a clinical trial per investigator's judgement.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    ARR-002

    Drug: ARR-002

Interventions

  • DrugARR-002

    ARR-002 will be administrated as specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Adverse Event (TEAE)

    AEs that occur or worsen on or after the first dose of study treatment

    Time frame: Baseline to 30 days after the last dose of study treatment

  2. Maximum Tolerated Dose (MTD)

    Incidence of dose-limiting toxicities (DLTs) and serious adverse events (SAEs)

    Time frame: Baseline to Day 21 of the first treatment cycle

Secondary outcomes

  1. Incidence of anti-drug antibody (ADA)

    The proportion of patients with positive ADA results.

    Time frame: Baseline to 30 days after the last dose.

  2. Objective Response Rate (ORR) - Phase Ia

    ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 24 months)

  3. Duration of Response (DOR)

    The time interval between the date of the earliest qualifying response and the date of disease progression or death for any cause, whichever occurs earlier.

    Time frame: Baseline to study completion (up to 24 months)

  4. Disease Control Rate (DCR)

    DCR is defined as the proportion of subjects achieving CR, PR, and stable disease (SD) after treatment.

    Time frame: Baseline to study completion (up to 24 months)

  5. Progression Free Survival (PFS) as assessed by investigator

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  6. Overall Survival (OS)

    OS is defined as the duration from the start of treatment to death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Aug 2027, 13 months after the start.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 13 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 10, 2026
StartActual
Jul 23, 2026
Primary completionEst.
Aug 2027
CompletionEst.
May 2029
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07755436
Lead sponsor
ArriVent BioPharma, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Jul 23, 2026
Primary completion
Aug 2027 (estimated)
Completion
May 2029 (estimated)
Last update
Sep 3, 2026

Study contacts

Clinical Operations
Contact
clinicaltrials.gov@arrivent.com
(888) 622-2827

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion